Sodium glucose cotransporter-2 (SGLT2) inhibitors have recently been shown, in large randomised placebo-controlled trials, to slow kidney disease progression in CKD down to an eGFR of at least 20 ml per min per 1.73 m2 irrespective of blood pressure, yet there is emerging evidence to suggest larger effects in those with higher levels of albuminuria [25]. Here, SLC5A2 is linked to kidney disorder.